 On Monday, biotechnology firm Allakos NASDAQ: ALLK announced a public offering that raised gross proceeds of approximately 150 million, sending ALLK stock soaring 25 in the morning session before paring back modestly heading into the early afternoon hours. Specifically, the company which focuses on developing lirentelimab AK002 and AK006 for the treatment of allergic and inflammatory diseases announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of 5.02 per share. 